These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21664218)

  • 21. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
    Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
    mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.
    Qi Z; Zhou L; Zhang Q; Ren L; Dai R; Wu B; Wang T; Zhu Z; Yang Y; Cui B; Wang Z; Wang H; Qiu Y; Guo Z; Yang R; Wang X
    Vaccine; 2010 Feb; 28(6):1655-60. PubMed ID: 20079562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
    Sha J; Kirtley ML; Klages C; Erova TE; Telepnev M; Ponnusamy D; Fitts EC; Baze WB; Sivasubramani SK; Lawrence WS; Patrikeev I; Peel JE; Andersson JA; Kozlova EV; Tiner BL; Peterson JW; McWilliams D; Patel S; Rothe E; Motin VL; Chopra AK
    Clin Vaccine Immunol; 2016 Jul; 23(7):586-600. PubMed ID: 27170642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.
    Do Y; Koh H; Park CG; Dudziak D; Seo P; Mehandru S; Choi JH; Cheong C; Park S; Perlin DS; Powell BS; Steinman RM
    Eur J Immunol; 2010 Oct; 40(10):2791-6. PubMed ID: 20812236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platform technology to deliver prophylactic molecules orally: an example using the Class A select agent Yersinia pestis.
    del Rio B; Fuente JL; Neves V; Dattwyler R; Seegers JF; Gomes-Solecki M
    Vaccine; 2010 Sep; 28(41):6714-22. PubMed ID: 20699130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.
    Hill J; Leary S; Smither S; Best A; Pettersson J; Forsberg A; Lingard B; Lipka A; Brown KA; Williamson ED; Titball RW
    Vaccine; 2009 Nov; 27(50):7073-9. PubMed ID: 19786138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amino acid residues 196-225 of LcrV represent a plague protective epitope.
    Quenee LE; Berube BJ; Segal J; Elli D; Ciletti NA; Anderson D; Schneewind O
    Vaccine; 2010 Feb; 28(7):1870-6. PubMed ID: 20005318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
    Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
    Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.
    Gallagher TB; Mellado-Sanchez G; Jorgensen AL; Moore S; Nataro JP; Pasetti MF; Baillie LW
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007644. PubMed ID: 31430284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the protective immune response to Yersinia pseudotuberculosis infection in mice vaccinated with an LcrV-secreting strain of Lactococcus lactis.
    Daniel C; Titecat M; Poiret S; Cayet D; Boutillier D; Simonet M; Sirard JC; Lemaître N; Sebbane F
    Vaccine; 2016 Nov; 34(47):5762-5767. PubMed ID: 27742220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fine-tuning synthesis of Yersinia pestis LcrV from runaway-like replication balanced-lethal plasmid in a Salmonella enterica serovar typhimurium vaccine induces protection against a lethal Y. pestis challenge in mice.
    Torres-Escobar A; Juárez-Rodríguez MD; Gunn BM; Branger CG; Tinge SA; Curtiss R
    Infect Immun; 2010 Jun; 78(6):2529-43. PubMed ID: 20308296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.
    Cornelius CA; Quenee LE; Overheim KA; Koster F; Brasel TL; Elli D; Ciletti NA; Schneewind O
    Infect Immun; 2008 Dec; 76(12):5588-97. PubMed ID: 18794281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen.
    Chiuchiolo MJ; Boyer JL; Krause A; Senina S; Hackett NR; Crystal RG
    J Infect Dis; 2006 Nov; 194(9):1249-57. PubMed ID: 17041851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yersinia pestis YadC: a novel vaccine candidate against plague.
    Murphy BS; Wulff CR; Garvy BA; Straley SC
    Adv Exp Med Biol; 2007; 603():400-14. PubMed ID: 17966436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
    Uppada SB; Bhat AA; Sah A; Donthamshetty RN
    Vaccine; 2011 Nov; 29(50):9352-60. PubMed ID: 22001881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen.
    Liu WT; Hsu HL; Liang CC; Chuang CC; Lin HC; Liu YT
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):58-69. PubMed ID: 17640293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells.
    Do Y; Park CG; Kang YS; Park SH; Lynch RM; Lee H; Powell BS; Steinman RM
    Eur J Immunol; 2008 Jan; 38(1):20-9. PubMed ID: 18081041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates.
    Sizemore DR; Warner EA; Lawrence JA; Thomas LJ; Roland KL; Killeen KP
    Hum Vaccin Immunother; 2012 Mar; 8(3):371-83. PubMed ID: 22327496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
    Eyles JE; Butcher WA; Titball RW; Hill J
    Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.